Submitted by dcc on Mon, 2019-08-05 16:40 Study Title: A Phase III, Randomized Study of Nivolumab (Opdivo) plus AVD or Brentuximab Vedotin (Adcetris) plus AVD in Patient (Age >/= 12 Year) with Newly Diagnosed Advanced Stage Classical Hodgkin LymphomaCIRB: Adult CIRB - Late Phase EmphasisLead Group: SWOGStatus: ActiveReview Status: Available to Open